Pharmaceutical and healthcare stocks experienced a significant increase in value on Thursday following a report from The Wall Street Journal indicating that the Trump administration might not impose tariffs on generic medications. This news brought relief to investors and the industry, which had been facing pressure after the announcement of 100% tariffs on branded and patented pharmaceutical products by the US government.
While the exclusion of generic medicines from tariffs is not yet confirmed, it is being seriously considered, with potential for decision adjustments based on ongoing internal discussions within the administration.
The Nifty Pharma and Healthcare indices showed a strong opening, each gaining 1.14%, reflecting widespread optimism in the market. Major pharmaceutical and healthcare companies saw an overall increase in their trading values.
Leading the surge was Aurobindo Pharma, with a 4.15% gain, followed by Lupin at 3.75% and Alkem Laboratories at 3.91%. Other notable increases included Cipla rising by 2.25%, Dr Reddy’s Laboratories advancing by 2.03% in the pharma index and by 2.00% in the healthcare index, Torrent Pharmaceuticals up by 2.17%, and Zydus Lifesciences gaining by 1.66% in the pharma index and 1.58% in the healthcare index. Sun Pharmaceutical Industries added 4.35%, while Divi’s Laboratories rose by 1.42%, demonstrating strong performance across the sector.
Market analysts attributed the rally to optimism surrounding the ability of Indian drug manufacturers, major suppliers of generics to the US, to continue operations without facing additional trade barriers.
The United States serves as India’s largest export market for pharmaceutical products, accounting for over 40% of the country’s total generic medicine exports. Any tariffs imposed on these exports would have significantly impacted the profit margins and global competitiveness of Indian companies.
The Trump administration, recognizing the US’s reliance on India and China for generic medicines and active pharmaceutical ingredients, has expressed intentions to reduce this dependency by enhancing local manufacturing capabilities.
Despite initial considerations under the Trade Expansion Act of 1962 for tariffs on generic drugs, the Trump administration appears unlikely to proceed with such measures following extensive internal deliberations. President Trump’s previous announcement of 100% tariffs on name-brand drugs did not specify the inclusion of generics, with final decisions pending further discussions with drug manufacturers and trade partners.
It is advisable to consult with a qualified broker or financial advisor before making any investment decisions based on the views expressed in this article.